Appl. No.

:

09/221,931

Filed

December 28, 1998

## AMENDMENTS TO THE CLAIMS

Claims 1-25. (Canceled)

Claim 26. (Currently amended) A method of inhibiting telomerase activity comprising a step of contacting cells exhibiting telomerase activity, comprising topically administering or injecting a catechin composition such that said cells are contacted by said composition, said composition comprising with a solution of a telomerase inhibitor comprising a catechin, wherein the concentration of the catechin in the solution is 15 µM epigallocatechin gallate, wherein the concentration of epigallocatechin gallate in the solution is 5 µM to 15 µM.

Claim 27. (Currently amended) The method according to claim 26, wherein the telomerase inhibitorcatechin composition comprises a green tea extract.

Claim 28. (Currently amended) The method according to claim 26, wherein the catechin composition is comprises epigallocatechin gallate, a combination of epigallocatechin gallate with a catechin selected from the group consisting of epigallocatechin, epicatechin gallate, or and epicatechin.

Claim 29. (Currently amended) The method according to claim 26, wherein the telomerase inhibitorcatechin composition further comprises a pharmaceutically acceptable carrier or diluent.

Claim 30. (Currently amended) The method according to claim 26, wherein the telomerase inhibitorcatechin composition comprises the one or more cateching in an amount of 90% to 95% by weight.

Claim 31. (Currently amended) The method according to claim 27, wherein the green tea extract is a dried powder that contains epigallocatechin gallate in an amount of at least 10 wt%.

Claim 32. (Currently amended) The method according to claim 26, wherein an effective amount of the telomerase inhibitor catechin composition is administered to a human subject having the cells exhibiting telomerase activity to contact the cells with the catechin.

Appl. No.

: 09/221,931

Filed

December 28, 1998

Claim 33. (Canceled)

Claim 34. (Currently amended) The method according to claim 3326, wherein the telomerase inhibitorcatechin composition is topically administered by injection or plaster.

Claim 35. (New) A method of inhibiting telomerase activity comprising contacting cells exhibiting telomerase activity with a solution of a telomerase inhibitor consisting essentially of epigallocatechin gallate at a concentration of 5  $\mu$ M to 15  $\mu$ M.